Cargando…
Targeting the PI3K signaling pathway in KRAS mutant colon cancer
Metastatic colorectal cancer (CRC) patients with v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are resistant to monoclonal antibody that targets the epidermal growth factor receptor such as cetuximab. BKM120 targets phosphatidylinositide‐3‐kinase (PIK3CA), but it is unknown w...
Autores principales: | Hong, Suntaek, Kim, SoYoung, Kim, Hye Youn, Kang, Myunghee, Jang, Ho Hee, Lee, Won‐Suk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735771/ https://www.ncbi.nlm.nih.gov/pubmed/26715098 http://dx.doi.org/10.1002/cam4.591 |
Ejemplares similares
-
Genomic Profiling of Patient-Derived Colon Cancer Xenograft Models
por: Lee, Won-Suk, et al.
Publicado: (2014) -
DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
por: Miller, Abigail L., et al.
Publicado: (2023) -
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022) -
Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model
por: Kim, Hye-Youn, et al.
Publicado: (2016) -
Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
por: Kim, Hye-Youn, et al.
Publicado: (2019)